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Clinical guidelines for the treatment of epilepsy have been published1, 2. A statement on management issues for women with
epilepsy has recently been produced by the American Academy of Neurology3 which has raised awareness of the issues facing
women with epilepsy. The communication presented here aims to review current literature on specific issues relating to women
with epilepsy, and proposes graded recommendations for its management within a UK health care framework.
Key words: guidelines; epilepsy; women; fertility; pregnancy; menopause.INTRODUCTION
Medline searches were performed (from 1966 to 1998)
on important issues in the clinical management of
women with epilepsy. Searches were limited to the En-
glish language and excluded case reports. Additional
material was obtained, if necessary, from the personal
literature collections of the Panel (i.e. The Women with
Epilepsy Guidelines Development Group). Where pub-
lished evidence was not available, the professional con-
sensus of the Panel was incorporated. These guidelines
are both evidence and experience based and the recom-
mendations will require judgement with regard to their
applicability in individual circumstances4.
The current status of each issue relating to the man-
agement of women with epilepsy was discussed by the
Panel, and statements and recommendations are pre-
sented, together with the supporting data. Each state-
ment was assigned a level of evidence (I, II or III) and
each recommendation was assigned a strength (A, B
or C) according to the level of supporting evidence
(Table 1). The criteria were based on a grading system
adapted from the Canadian Task Force Classification5
which was used in existing guidelines for the manage-
ment of poorly controlled epilepsy1.1059–1311/99/040201 + 17 $12.00/0These guidelines are aimed at clinicians who manage
women with epilepsy.
MATERIALS AND METHODS
Adolescence and epilepsy
Adolescence is an important time to review the diagno-
sis of both epilepsy and the epilepsy syndrome, because
of the implications and decisions which should be made
regarding antiepileptic drug (AED) treatment. Advice
on relationships, contraception, the consequences of
AED treatment, employment, driving and psychoso-
cial issues needs to be provided at this time6.
Review of the diagnosis
It is important to recognize that at least 10% of
teenagers thought to have epilepsy actually have a non-
epileptic disorder7. An underlying organic cause for the
epilepsy should be sought at this time. Temporal lobe
epilepsy (due to hippocampal sclerosis) may present in
early adolescence or early adult life, as may a tumour. In
rare cases, the development of epilepsy in adolescence
may herald the onset of a progressive neurodegenera-c© 1999 BEA Trading Ltd
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Table 1: Grading scheme for recommendation strengths and levels of evidence.
Level of evidence
I—Well-designed, randomized, controlled trials, systematic reviews or meta-analyses
II—Well-designed (but non-randomized), prospective- or retrospective-controlled studies or other observational studies
III—Uncontrolled trials or descriptive studies or consensus agreed in reports from expert committees or other respected authorities
Strength of recommendations
A—Based directly on level I evidence
B—Based directly on level II evidence or extrapolated from level I evidence
C—Based directly on level III evidence or extrapolated recommendation from level I or II evidence
Adapted from reference 1.tive disorder. Common misdiagnoses include syncope,
non-epileptic attack disorder and migraine. A normal
computerized tomography (CT) scan undertaken previ-
ously should not preclude a repeat scan with magnetic
resonance imaging (MRI) in a teenager/young adult
with poorly controlled epilepsy8. Poorly controlled pa-
tients are defined as those who continue to have seizures
despite initial assessment and treatment with one or
more AED and who continue to feel disabled by their
seizures1.
Puberty is a problematic stage for females due to
psychological, social and hormonal changes. Repeated
seizures occurring during childhood can affect en-
docrine systems and growth so that a proportion of girls
with epilepsy will not be as tall as their counterparts,
will be obese, and will have a delayed menarche. Cos-
metic side-effects of AEDs may cause concern in this
age group, e.g. the coarsening of facial features, gin-
givitis, acne and hirsutism occurring with phenytoin,
and weight gain occurring with valproate, gabapentin
and vigabatrin.
In adolescence, idiopathic generalized and
localization-related epilepsies (including temporal
lobe epilepsy) are common. Juvenile myoclonic
epilepsy may include asymmetrical or symmetrical
myoclonic seizures (‘jerks’) of the upper limbs, par-
ticularly in the early morning or following sleep de-
privation. Brief absence attacks need to be identified
to permit appropriate treatment. Epilepsy, with gener-
alized tonic–clonic seizures on awakening, may also
develop at this time9.
Electroencephalography aids the diagnosis of
epilepsy syndromes and should be undertaken in all
patients who present with new or changing seizures.
The late childhood to adolescence period is a time
when epilepsy is more likely to arise than in any other
time of life and it is also a time when pre-existing
seizure disorders worsen10, 11. During adolescence the
young woman should be made aware that her condition
and the treatment she is taking may affect her future fer-
tility. These issues, taken together with the influence of
over-protective parents, may lead to low self-esteemand lack of confidence unless timely and accurate ad-
vice and counselling are provided. It is therefore recom-
mended that a full review of the patient be undertaken
at this time.
Adolescence and epilepsy—statements and
recommendations
 Adolescence is an important time to review the di-
agnosis of epilepsy (III).
 Advice should be given on the issues relating to the
confirmed diagnosis of epilepsy (C).
Epilepsy, menstrual cycle and fertility
The diagnosis of epilepsy and the use of AEDs present
women of childbearing age with many problems, as
both the disease and its treatment can alter the men-
strual cycle and fertility. There are also problems with
drug interactions, particularly with oral contraceptives.
Furthermore, AEDs are associated with teratogenic ef-
fects. The AEDs and the seizure disorder can cause
adverse effects during pregnancy, and conversely, the
menstrual cycle and pregnancy can affect a seizure
disorder due to hormonally induced alteration of the
seizure threshold. All women with epilepsy should be
counselled about fertility issues at their review consul-
tation.
Effect of epilepsy on fertility
There is decreased fertility amongst women aged 25
to 39 years with treated epilepsy12. This has been hy-
pothesized to be due to a reduction in marriage rates
for people with epilepsy13–15. However, even within
marriage, fertility rates are lower than in the general
population12. There is a higher incidence of menstrual
disorders in women with partial seizures of temporal
lobe origin (35%) when studied over three cycles, com-
pared with 8% in a control group16.
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study of 65 women with epilepsy, an increased inci-
dence of polycystic ovary syndrome was noted amongst
64% (14/22) women taking valproate monotherapy17.
In a study of 238 women with epilepsy, 45% on val-
proate monotherapy (13/29 women) displayed men-
strual irregularities (amenorrhoea, oligomenorrhoea,
prolonged cycles and irregular menstruation); 60% of
these women also displayed polycystic ovaries and
30% had elevated serum testosterone concentrations.
These effects were more common in women begin-
ning valproate before the age of 2018. Evidence from
a group of 12 women with epilepsy suggests that stop-
ping valproate therapy leads to a reversal of hyper-
insulinaemia, hyperandrogenism and low serum high-
density lipoprotein cholesterol19.
Luteinizing hormone pulse frequency has been found
to be increased20 or variable in women with epilepsy21
and this pre-disposes towards the development of poly-
cystic ovary syndrome22.
The polycystic ovary syndrome includes hyperan-
drogenism (with raised testosterone levels), multiple
ovarian cysts, anovulatory cycles, hirsutism, and in 30–
50% of patients, obesity. The prevalence of the poly-
cystic ovary syndrome in women without epilepsy is
between 4% and 19%, depending on how the syndrome
is defined and assessed23. The true prevalence of the
condition in women with epilepsy is unknown, but is
thought to be higher than in women without epilepsy,
even in those not taking AED medication24. The con-
dition is thought to be more prevalent in those women
taking sodium valproate17.
The hormonal disturbances of the polycystic ovary
syndrome may exacerbate the seizure disorder22. Since
anovulatory cycles expose the brain to continuous
oestrogen without cyclical progesterone, administra-
tion of progesterone25, or the synthetic progestogen,
medroxyprogesterone acetate26, may be helpful.
Fertility—statements and recommendations
 All women with epilepsy should be counselled
about their fertility and the possible effects of their
AED treatment (C).
 There is decreased fertility amongst women with
epilepsy (II).
 There is an increased incidence of anovulatory cy-
cles amongst women with partial seizures (II).
 The true prevalence of polycystic ovary syndrome
amongst women with epilepsy, even if they are not
taking AEDs, may be higher than in women with-
out epilepsy and the prevalence is higher still in
those taking sodium valproate (II).Catamenial epilepsy
Catamenial seizures refer to an increase in seizures
around the time of the menses either just before or
during the first few days of menstruation. Catamenial
seizures may be uncommon, for example, occurring
in 12.5% of 40 women with epilepsy, despite 78% of
women claiming that their seizures occurred near the
time of menstruation27. Anovulatory cycles tend to be
associated with an increase in seizure frequency in the
second half of the menstrual cycle, whilst ovulatory
cycles can have one or two peaks in seizure frequency
around the time of menstruation and/or ovulation28, 29.
Hormonal environment. Catamenial seizure exacer-
bations may be related to the changing sex hormone
concentrations during the menstrual cycle. Oestrogens
lowered the seizure threshold in the hippocampus and
amygdala, and elicited seizure activity when directly
applied to the cortex of animals30.
Conversely, progestogens and their metabolites ap-
pear to have anticonvulsant properties which may be
mediated by the type A gamma-aminobutyric acid re-
ceptor31.
Further evidence for the role of alterations in sex hor-
mone concentrations in catamenial epilepsy includes a
decreased number of seizures during the luteal phase
when progesterone concentrations are highest32, 33, and
the suggestion that a pre-menstrual increase in seizures
is related to a reduction in progesterone concentration.
Other factors may be associated with catamenial
epilepsy, including changes in AED pharmacokinetics,
and menstrually related mood changes. An increased
incidence of pre-menstrual tension has been reported
amongst women with catamenial seizures (75%) com-
pared to other women with epilepsy (43%)34.
Treatment issues. Many therapeutic interventions
have been evaluated in catamenial epilepsy with vary-
ing degrees of success. In the 1950s acetazolamide
was advocated35, 36 and it is still used today in some
patients. Over the past decade, there has been some
research on hormonal manipulation, with the aim of
increasing relative progesterone concentrations or con-
verting anovulatory to ovulatory cycles. In women with
catamenial epilepsy, progesterone produced a decrease
in seizure frequency37 but norethisterone failed to show
any antiepileptic effect38.
An alternative treatment for women with epilepsy is
a benzodiazepine but continued prescription can lead to
tolerance and dependence. This problem can be over-
come using an intermittent regimen39 such as that em-
ployed in a double-blind, placebo-controlled crossover
assessment of clobazam in women with catamenial
seizures40. For women already on AEDs, intermittent
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gested when a seizure increase is anticipated.
For women with catamenial epilepsy in whom low
pre-menstrual progesterone levels may be a factor, an
intermittent perimenstrual progesterone supplement is
suggested, or a synthetic progestogen during days 10–
26 of the menstrual cycle. A combined oral contra-
ceptive pill may be prescribed. If clobazam or a pro-
gestogen are unsuccessful, danazol or goserelin may
be prescribed for pre-menstrual symptoms but only by
those physicians who are experienced in their use. The
oestrogen analogue, clomiphene41, may be useful but
should only be used by those experienced in its use, as
ovarian hyperstimulation is potentially dangerous.
For those rare women not already taking AEDs, and
who have established, isolated catamenial epilepsy, one
of the following regimens may be helpful as an al-
ternative to a regular AED regimen: intermittent peri-
menstrual clobazam (10–30 mg/day); combined oral
contraceptive pill, depot progestogen therapy; or peri-
menstrual progestogen (oral or suppository).
Catamenial epilepsy—statements and
recommendations
 Catamenial epilepsy occurs in about 12% of women
with epilepsy (II).
 In ovulatory cycles there may be two seizure peaks,
perimenstrually and at midcycle (II).
 For women already on AEDs, the currently rec-
ommended treatment is intermittent clobazam on
days when seizure increase is anticipated (B). Alter-
native therapies include acetazolamide given peri-
menstrually or progestogens (C).
 For those rare women not already taking AEDs, the
following are alternatives: intermittent perimen-
strual clobazam (10–30 mg/day); combined oral
contraceptive pill, depot progestogen therapy; or
perimenstrual progestogen (III).
Contraception in epilepsy
There are no contraindications to the use of non-
hormonal methods of contraception in women with
epilepsy.
An interaction between hepatic enzyme-inducing
drugs and the combined oral contraceptive pill was first
noted when the dose of oestradiol in the oral contra-
ceptive pill was reduced from 100 g to 50 g. A
higher incidence of breakthrough bleeding and contra-
ceptive failure has been noted amongst women with
epilepsy on the oral contraceptive pill42, 43 and this
may be due to a relative oestrogen deficiency44. The
drugs implicated include phenytoin, phenobarbitone,primidone, carbamazepine42 and more recently, topi-
ramate (Topiramate Summary of Product Characteris-
tics). Clinicians should consider carefully the implica-
tions of using these agents in women with child-bearing
potential because of their effect on the efficacy of oral
contraceptives. Even with higher dose combined oral
hormonal contraceptive methods, complete protection
from pregnancy is not achievable in women taking
hepatic enzyme-inducing AEDs. Non-enzyme induc-
ing AEDs—sodium valproate, benzodiazepines, viga-
batrin, gabapentin, lamotrigine and tiagabine—do not
show any interactions with the combined oral contra-
ceptive pill. Oxcarbazepine is considered to be a weak
enzyme-inducing agent45.
In women taking phenobarbitone, primidone, pheny-
toin, carbamazepine and topiramate, the starting dose
of ethinyl oestradiol should be 50g/day and it may be
necessary to increase the ethinyl oestradiol dose to 75–
100 g if breakthrough bleeding occurs. Nausea may
occur with these high daily doses. An alternative is to
take three packs of a higher dose oral contraceptive pill
without a break in between (‘tricycling’) and then have
four days without taking the pill. Women need advising
that even on a higher dose combined contraceptive pill
and with normal cycles, full efficacy cannot be guar-
anteed. However, pregnancy rates are lower when oral
contraceptives are used in epilepsy (approximately 7
in 100 woman-years) compared with barrier methods
(failure rate of 15–20 in 100 woman-years)42, 46.
Medroxyprogesterone injections appear to be effec-
tive in women with epilepsy. No adjustment of dosing
frequency may be needed in women taking enzyme-
inducing AEDs as the rate-limiting step of elimination
is hepatic blood flow and not enzyme activity. However,
experience of some Panel members suggests that the
usual dosing frequency of one medroxyprogesterone
injection every 12 weeks could be changed to one injec-
tion every 10 weeks in women taking enzyme-inducing
AEDs. Levonorgestrel implants are contraindicated in
women taking enzyme-inducing AEDs as there is an
unacceptably high failure rate47. It must be assumed
that the efficacy of progesterone-only oral contracep-
tives is affected by enzyme-inducing AEDs, although
it is unknown by how much24. Women should be ad-
vised not to rely solely on a progesterone-only pill for
contraception if they are taking an enzyme-inducing
AED, as it may be less effective than the combined
oral contraceptive pill.
If appropriate, the morning-after contraceptive pill
can be used in women with epilepsy after unprotected
sexual intercourse. There are no data on whether a
change in dose of the morning-after contraceptive pill
is required in women taking AED medication; some
practitioners use a slightly higher dose in those women
taking enzyme-inducing AEDs.
Best practice guidelines for the management of women with epilepsy 205Contraception—statements and recommendations
 There are no contraindications to the use of non-
hormonal methods of contraception in women with
epilepsy (III).
 For women on non-enzyme-inducing AEDs
(sodium valproate, benzodiazepines, vigabatrin,
gabapentin, lamotrigine, tiagabine), all current con-
traceptive methods are suitable (III).
 Hormonal forms of contraception are affected
by enzyme-inducing AEDs. Women taking these
forms of contraception should be counselled on
their risks and benefits (C).
 For women on enzyme-inducing AEDs (phenytoin,
phenobarbitone, primidone, carbamazepine, topi-
ramate) wishing to take the combined oral contra-
ceptive pill:
— start with a 50g ethinyl oestradiol dosage (C);
— if breakthrough bleeding occurs, increase the
dose of ethinyl oestradiol to 75 or 100 g/day
or consider giving three packs of the pill with-
out a break (‘tricycling’) (C).
 Even on a higher dose combined oral contraceptive
pill with normal cycles, full oral contraceptive effi-
cacy cannot be guaranteed in women with epilepsy
taking enzyme-inducing AEDs (III).
 The progesterone-only pill may be less effective
than the combined oral contraceptive pill in women
taking enzyme-induced AEDs (III).
 Medroxyprogesterone injections appear to be ef-
fective (III).
 Levonorgestrel implants are contraindicated (III).
 If appropriate, the morning-after contraceptive pill
can be used in women with epilepsy after unpro-
tected sexual intercourse (C); a slightly higher dose
may be needed in women taking enzyme-inducing
AEDs (C).
Sexuality
The majority of women with epilepsy appear to have
normal sex lives, although in some women with
epilepsy both the desire and arousal phases may be
inhibited. This is slightly but significantly more likely
to occur than in women who do not have epilepsy and
will impair quality of life48.
Psychological factors that can inhibit desire or
arousal in women with epilepsy include over-
protection in childhood and adolescence, a poor self-
image, and the lack of ability to ‘let go’ during thesexual act for fear of a seizure (or the partner’s fear of
a seizure).
Research on sexual function in women has con-
centrated on the influence of AEDs, particularly the
enzyme-inducing drugs such as phenobarbitone, which
may alter sex hormone binding. Two studies found an
association between sexual functioning and sex hor-
mone binding changes: other studies which suggested
that this was not an important cause of sexual dysfunc-
tion included only a small number of women48.
Although previous methodological flaws have been
largely overcome, recent studies have been mainly con-
ducted on women attending specialist epilepsy clinics,
or belonging to epilepsy organizations, thus possibly
introducing bias. Direct comparison of sexual respon-
siveness between women with epilepsy and their unaf-
fected peers has not been carried out.
Epilepsy itself independently affects neuroendocrine
functioning in women. In men, epilepsy-related
changes in hypothalamic endocrine function have an
effect on sexual arousal48, but it is less clear if this is
the case in women since female sexuality may be more
dependent on psychological rather than endocrine fac-
tors49.
Sexual feelings occurring as part of a partial seizure
are usually feelings of sexual arousal and seem only to
have been reported in women50. Sexual behaviours can
also occur both ictally and post-ictally, are usually in-
appropriate, and after a seizure, are related to post-ictal
confusion.
Many women with epilepsy do not spontaneously
complain of sexual difficulty. A short, standard sex-
ual history49 should form part of the assessment of all
women with epilepsy at some point. If a problem is
found in addition to psychological assessment, neu-
roendocrine evaluation may be needed48, and appro-
priate referral made for treatment24.
Sexuality—statements and recommendations
 Sexual desire and sexual arousal may be affected by
epilepsy or by the treatment of epilepsy in women
(II).
 The majority of women with epilepsy have normal
sex lives (II).
 Sexual feelings or behaviours may occur during
partial seizures (II).
 Enquiry about sexual feelings and function should
be part of the standard assessment of women with
epilepsy (C).
 If a disorder of desire or arousal is discovered, ex-
pert psychological and neuroendocrine evaluations
are recommended (C).
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Women need to have their epilepsy thoroughly re-
assessed before becoming pregnant51 as some condi-
tions causing epilepsy may be better dealt with be-
fore pregnancy, e.g. those for which neurosurgical
treatment may be appropriate. Furthermore, formal
pre-conception counselling (and re-investigation, if
needed) should be available to all women with epilepsy
who are considering pregnancy. Counselling should
begin at the time of diagnosis of epilepsy and be re-
peated at intervals throughout its management. Some
hospitals offer clinics for teenagers and formal pre-
conception clinics but there are few of these and all
too often women with epilepsy do not present until a
pregnancy has occurred. This situation leaves room for
improvement.
Pre-conception counselling involves making women
with epilepsy aware of a number of issues relating to
future pregnancy, including methods and consequences
of prenatal screening, teratogenicity, labour and child-
care. The main aim of pre-conception counselling is
to ensure that women embark upon pregnancy with a
minimum of risk factors, fully aware of any risks and
benefits of treatment, and able to make informed deci-
sions about the pregnancy.
Seizure and AED management
Before conception, the continuing need for AED treat-
ment should be reviewed, based on Medical Research
Council criteria52. Women should enter pregnancy hav-
ing complete seizure control or as few seizures as pos-
sible. If a patient has been seizure-free for at least 2–
3 years, consideration may be given to withdrawing
AEDs to reduce the potential teratogenic risk. How-
ever, many women do not wish to withdraw from drug
therapy even when seizure-free as this may affect their
eligibility to drive and continue with work and normal
activities. The lowest effective dose of the most appro-
priate AED should be continued, aiming for monother-
apy where possible. Currently, the UK Driver and Ve-
hicle Licensing Agency recommend not driving from
the commencement of the period of withdrawal and for
a period of 6 months after cessation of treatment, even
if there are no seizures53.
Teratogenicity in perspective
As with all women contemplating pregnancy, advice
should be given about maintaining good general health
in relation to exercise, diet, smoking and alcohol con-
sumption. Although a major concern of women with
epilepsy who are contemplating pregnancy is the tera-
togenic potential of AEDs, it is important to put these
risks in perspective. Even women on no medicationand with no seizures but who have had epilepsy have a
slightly increased risk54. The background risk of sig-
nificant fetal malformation is approximately 3% in de-
veloped countries and the consensus from many studies
is that this increases to 7% if one AED is taken and to
15% if two or more are taken43, 55, 56. Most major mal-
formations develop at an early stage in pregnancy, often
before the woman knows she is pregnant. Exposure in
the later stages of pregnancy may still lead to minor
morphological abnormalities57–60. Some AED combi-
nations appear to carry a high risk, e.g. valproate plus
carbamazepine plus phenytoin or phenobarbitone has
been associated with a 58% malformation rate, possibly
due to accumulation of toxic metabolites61. The mech-
anisms whereby AEDs are teratogenic have not been
definitely established. Possibilities include the forma-
tion of epoxide and arene oxide metabolites, cytotoxic
free radicals, and effects on fetal heart rate leading to
hypoxia. Folic acid deficiency is also a possible cause.
Is there any difference between the AEDs in terms of
teratogenicity?
There is no conclusive evidence for a significantly dif-
ferent teratogenic risk from phenytoin, valproate, car-
bamazepine or phenobarbitone. There have been sug-
gestions that valproate is more teratogenic than other
AEDs43, 61. In a prospective study of women who took
AEDs during pregnancy (monotherapy and polyther-
apy), phenobarbitone was associated with the high-
est relative risk, followed by phenytoin and carba-
mazepine; there were insufficient numbers of women
treated with valproate to assess the risk associated
with this drug62. Comparison of studies is confounded
by patients having different types and severities of
epilepsy, by taking different doses and combinations
of drugs, and insufficient studies of monotherapy to
draw definitive conclusions.
Phenytoin. Phenytoin should be avoided in women
with child-bearing potential, particularly in adoles-
cence, as it has a number of undesirable side-effects.
Phenytoin is particularly associated with an increased
risk of cleft lip and palate as well as dysmorphic fea-
tures such as nail and distal phalangeal hypoplasia and
craniofacial abnormalities43, 59, 63, 64.
Phenobarbitone. Phenobarbitone has been associ-
ated with congenital heart defects, facial clefts, and
a specific pattern of minor anomalies and dysmorphic
features55, 65, 66.
Valproate. Doses of valproate greater than
1000 mg/day carry a greater risk of spina bifida than
lower doses67, possibly due to high peak serum concen-
trations of valproate. Confirmatory studies are required
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slow-release preparations minimize this risk by reduc-
ing peak plasma levels. A ‘fetal valproate syndrome’
has been suggested as being associated with dysmor-
phic features and developmental delay68. Valproate in
pregnancy has been associated with a 1–2% risk of
neural tube defects, particularly an open lumbosacral
myelocoele, against a background risk of 0.2–0.5%.
There is also an increased incidence of cardiovascular
and urogenital malformations43. Thus, although val-
proate may the most suitable drug for some women
with epilepsy, the risks and benefits should be carefully
considered and discussed with the patient.
Carbamazepine. Carbamazepine was once consid-
ered to be the least teratogenic of the older AEDs, but
recent studies have shown an association between car-
bamazepine and congenital malformations in the same
order of magnitude as for barbiturates and phenytoin.
However, these studies have included small numbers
and uncontrolled data and need to be replicated before
being regarded as definitive. Furthermore, the types of
malformation are different59. In one study there was
a 0.9% reported risk of neural tube defects in the off-
spring of mothers who took carbamazepine through
pregnancy69. There have also been reports of reduced
head circumference at birth, of developmental delay in
20% of infants70 and of dysmorphic features71.
Dysmorphic features
Dysmorphic features, including epicanthal folds, long
philtrum, flat nasal bridge, digital hypoplasia and hy-
pertelorism, are undesirable and cause some disability
but they do not result in serious impairment or death.
Such abnormalities have been ascribed to syndromes
related to specific AEDs, such as the ‘fetal hydantoin
syndrome’72, and subsequently revised to recognize a
‘fetal AED syndrome’. The extent of the causal rela-
tionship with AEDs has been questioned and evidence
has been put forward for maternal genetic factors influ-
encing the development of minor abnormalities such as
epicanthus and micrognathia54, 73. Larger prospective
studies of women treated with monotherapy are neces-
sary to resolve these issues. Valproate exposure in utero
is associated with a combination of facial dysmorphic
patterns distinct from those associated with phenytoin
exposure74, 75.
Digital and craniofacial hypoplasia tend to resolve
over the first few years of life43. Some investigations
have reported that babies exposed to AEDs in utero tend
to be small at birth and have slow postnatal growth and
cognitive development, but controlled data are lacking.
Most studies have suggested that there is a very low
risk of prenatal AED exposure leading to low intelli-
gence76. Other factors affecting a tendency to developa low intellect include maternal and paternal genetic
predisposition and psychosocial influences.
Animal studies
Safety data from limited animal studies suggest that
some AEDs appear to show no teratogenic effects. At
present there are insufficient monotherapy data in hu-
mans to predict the risk of teratogenicity. To date, lam-
otrigine, gabapentin and tiagabine have not been shown
to produce malformations in animal studies77, 78. Viga-
batrin has been associated with cleft anomalies in New
Zealand white rabbits64. Topiramate is teratogenic in
mice, rats and rabbits, and crosses the placental barrier
(Topiramate Data Sheet).
Use of folic acid
The UK Medical Research Council study, including
women who had previously given birth to an infant with
a neural tube defect, found that 4 mg/day of folic acid
given prior to conception was associated with a 72%
protective effect79. Folic acid supplementation has also
been shown to have a protective role in the primary pre-
vention of neural tube defects80–82. Although there has
been no specific study of the effect of folic acid supple-
mentation on the risk of neural tube defects and other
congenital malformations in women taking valproate or
other AEDs, extrapolations have been made from pub-
lished studies in the general population and therefore
a daily dose of 5 mg of folic acid is recommended be-
fore and during pregnancy for all women taking AEDs,
starting before conception and continuing until at least
the end of the first trimester.
A daily dose of 5 mg of folic acid is probably more
than is needed to achieve a maximal reduction of risk.
A daily intake of at least 0.4 mg/day has been recom-
mended for the general population82. The larger dose,
however, does not appear to cause adverse effects, un-
less the patient has covert pernicious anaemia.
Prospective registers
In clinical evaluations of AEDs, women with child-
bearing potential are either excluded or encouraged to
take adequate contraceptive measures. Therefore, very
few pregnancies occur during clinical trials, and those
that do, often end in therapeutic abortions.
In the UK, the British Neurological Surveillance Unit
has established a prospective pregnancy register for pa-
tients taking AEDs. Over the course of 2 years approx-
imately 400 pregnancies have been registered by neu-
rologists, obstetricians and general practitioners. The
register has been granted ethical approval and aims to
audit the incidence of congenital malformations in the
offspring of patients taking AEDs. It should be noted
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Table 2: Notification of new AEDs to UK Prospective Register (interim results, March 1998).
Drug Total No malformation Malformation present
(no. of notifications)* outcomes
Live Abortion Live Abortion Intrauterine
birth birth death
Spontaneous Therapeutic Spontaneous Therapeutic
Lamotrigine .n D 116/ 67 55 7 1 2a;b 1c 0 1d
Vigabatrin .n D 40/ 27 24 1 0 1e 1f 0 0
Gabapentin .n D 35/ 21 15 2 1 3g;h;i 0 0 0
a Live born infant—mid-gut malrotation and cerebral palsy. b Live born infant—hypospadias. c Spontaneous abortion—trisomy 21.
d Inter-uterine death at 24 weeks—thoracic cage abnormality and lung hypoplasia. e Live born infant—hypospadias. f Spontaneous
abortion—trisomy 21. g Live born infant—ventricular septal defect. h Live born infant—bilateral orofacial clefts. i Live born
infant—hypospadias. Includes use in monotherapy and polytherapy: no inferences can be drawn from these figures.that these data have been obtained on first trimester
exposures to AEDs in women receiving monotherapy
and polytherapy. Preliminary data are shown in Table 2.
It is only with continued support of these prospective
registers that the information clinicians require to ade-
quately counsel patients may be obtained (the address
of the Register is given in the Appendix).
Genetic predisposition
Many women ask about the risks of passing epilepsy to
their children and the majority can be assured that their
child is not at risk. In specific cases there may be an
underlying genetic cause. For idiopathic generalized
epilepsy, the risk of a child developing the condition
is 5–20% if there is one affected first degree relative
and over 25% if two first degree relatives are affected.
Thus the risk of a patient with idiopathic generalized
epilepsy having an affected child is about 9–12%, and
the risk is 3% in children of patients with cryptogenic
localization-related (partial) seizures83.
Pre-conception counselling and
teratogenicity—statements and recommendations
 Pre-conception information should be offered to all
females with child-bearing potential (C).
 If changes in AED medication are to be made they
should be completed before conception (B).
 If AED treatment is needed, a single agent is pre-
ferred (B).
 The risk of fetal malformation is doubled in women
receiving treatment for epilepsy compared with the
general population (3% in the general population,
7% with one AED, 15% with two or more AEDs)
(II). Some combinations of polytherapy are partic-
ularly teratogenic (II).
 Most major malformations occur at an early stage
in pregnancy, often before the woman knows she ispregnant (I).
 Women with epilepsy who are planning a preg-
nancy should take folic acid 5 mg daily in the pre-
conception period and throughout the pregnancy
(B).
 The use of phenytoin, valproate, carbamazepine
and phenobarbitone has been associated with an
increased risk of major malformations and minor
morphological anomalies (II).
 Although valproate may the most suitable drug for
some women with epilepsy, the risks and benefits
should be carefully considered and discussed with
the patient (C).
 It is not known whether vigabatrin, gabapentin,
lamotrigine, topiramate and tiagabine are associ-
ated with a risk of fetal abnormalities in humans.
Gabapentin, lamotrigine and tiagabine are not as-
sociated with fetal abnormalities in animal studies
(III).
 All pregnancies occurring in women with epilepsy
should be reported to the appropriate UK register,
regardless of whether or not AEDs are being taken
(C).
Management of pregnancy and birth in epilepsy
Effect of pregnancy on epilepsy
Most women with epilepsy do not experience an in-
crease in seizures whilst pregnant84. Of those women
who do have an increase in seizures (between 8% and
46%)85, the increase can often be attributed to factors
such as poor compliance with prescribed AEDs (some-
times compounded by vomiting), inappropriate reduc-
tion of AED therapy, a pregnancy-related fall in plasma
drug concentrations, and sleep deprivation86, 87. Conse-
quently, the patients’ seizures should be monitored and
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in seizure frequency is more likely in women with a
high pregravid seizure frequency or multiple seizure
types. An episode of status epilepticus occurs in less
than 1% of pregnancies. The risk of seizures is greatest
in the delivery period with tonic–clonic seizures com-
plicating labour in 1–2% of cases and a further 1–2%
in the following 24 hours88.
In contrast, up to 50% of women report that their
epilepsy is better controlled during pregnancy, for rea-
sons which include avoidance of excessive fatigue, bet-
ter compliance and hormonal changes87, 89.
Effect of epilepsy on pregnancy
Most pregnancies are uneventful in women with
epilepsy and most of the babies delivered are healthy87.
More recent studies have not indicated any increased
risk of obstetric complications in women with epilepsy,
while other studies report an approximately 1.5–3 times
increase in the risk of common complications such as
toxaemia, pre-eclampsia, placental bleeding and pre-
mature labour and a 1.2–2 times increase in perinatal
mortality90. Many studies are retrospective or based on
registries and are likely to be complicated by ascertain-
ment bias89.
There is no evidence that simple partial, complex par-
tial, absence and myoclonic seizures adversely affect a
pregnancy or developing fetus, other than by the effects
of trauma91. Prospective studies indicate that there is no
association between tonic–clonic seizures during preg-
nancy and malformations54, 92. Anecdotally, tonic–
clonic seizures may cause fetal bradycardia in hu-
mans93 or miscarriage94 but definitive data are lacking.
Management of epilepsy during pregnancy
Having established the patient on optimal monother-
apy, if possible, prior to conception, subsequent man-
agement of AED treatment during pregnancy is gen-
erally straightforward, but requires careful attention.
Patients should understand and agree with their pre-
scription and the rationale for any dose change.
Serum AED concentrations often fall during preg-
nancy, particularly in the first and third trimesters, and a
pre-conception baseline value may be helpful59, 86, 95.
Many factors may contribute to the change in AED
pharmacokinetics including: increased hepatic or re-
nal clearance, increased plasma volume and reduced
plasma albumin concentration and protein binding.
Reduced bioavailability is probably not an important
factor.
The value of measuring plasma drug levels routinely
during pregnancy is still uncertain. When such mea-
surements are carried out, assessment of the unbound
drug fraction is the method of choice96.Prenatal diagnosis of malformations
Since epilepsy is associated with an increased risk of
fetal malformations, women with epilepsy should be
referred by their obstetric/gynaecological consultant to
a specialist centre for a high-quality ultrasound scan.
They will also usually require more than one scan plus
appropriate blood tests and possible amniocentesis. Ul-
trasound studies from about 18 weeks can identify ma-
jor cardiac, facial and limb anomalies and recogniz-
ing increased nuchal translucency on the scan between
weeks 10–14 may give early indication of major car-
diac defects97. Patients and families need to be advised,
however, that even the most sophisticated scans cannot
detect 100% of abnormalities.
Management of labour
One to two percent of women with active epilepsy will
have a tonic–clonic seizure during labour, and a fur-
ther 1–2% will have such a seizure in the following
24 hours88, 89. Generalized tonic–clonic seizures are
likely to result in more profound hypoxia than in the
non-gravid state, because of increased maternal oxygen
requirements, and this may have deleterious effects on
the fetus. Thus it is recommended that the delivery take
place in an obstetric unit with facilities for maternal and
neonatal resuscitation.
The patient’s regular AEDs should be continued
throughout labour. If necessary, all drugs may be
given by nasogastric tube; phenytoin (as fosphenytoin),
valproate, phenobarbitone, diazepam and clonazepam
may be given parenterally.
Administration of intramuscular corticosteroids
(such as dexamethasone) given to a woman in pre-
mature labour can help to prevent respiratory distress
syndrome or intraventricular haemorrhage in the in-
fant. An increased corticosteroid dose is necessary in
women taking hepatic microsomal enzyme-inducing
AEDs (e.g. phenytoin, phenobarbitone, primidone, car-
bamazepine and topiramate)98.
Most women with epilepsy have normal vaginal
deliveries93, 99, 100. Over-breathing, sleep deprivation,
pain and emotional stress increase the risk of seizures
during labour and it is appropriate to consider epidu-
ral anaesthesia early on, to minimize these factors.
An elective Caesarean section may be appropriate if
frequent tonic–clonic or prolonged complex partial
seizures occur in the last weeks of pregnancy. Intra-
venous lorazepam may be an appropriate acute treat-
ment for serial seizures during labour93.
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the newborn
Vitamin K1 deficiency bleeding carries a mortality rate
of over 30%101. It is due to deficiency of factors II, VII,
IX and X and is more likely to occur in the offspring
of women who have taken hepatic enzyme-inducing
drugs during pregnancy102, 103. A dose of 20 mg/day
of vitamin K1 given orally in the last month of preg-
nancy may protect against the problem. Infants born of
women with epilepsy should receive 1 mg of vitamin
K1 intramuscularly at birth. The putative association
of this treatment with childhood neoplasia is unwar-
ranted104–110. Infants should receive intravenous fresh
frozen plasma if there is evidence of bleeding or if the
concentrations of two or more of factors II, VII, IX or X
fall to less than 25% of normal.
The puerperium
If the dose of an AED has been increased during preg-
nancy, it is usually advisable for it to be gradually re-
duced to the pre-conception dose over the few weeks
following delivery, to reduce the risk of maternal tox-
icity. However, if the increased dose does not lead to
toxic symptoms and there is a sustained improvement
in seizure frequency, the regimen should not be altered.
Development of seizures in pregnancy
The annual incidence of new cases of epilepsy in the
reproductive years from the teens to the age of 40
is 20–30 per 100 000 per year111. Thus, the devel-
opment of epilepsy during pregnancy is not uncom-
mon. A few specific aetiologies are associated with
pregnancy, such as an enlarging meningioma or ar-
teriovenous malformation or other vascular disease.
The risk of ischaemic stroke is increased by a factor
of 10 in the last 6 months of pregnancy, and approxi-
mately 4% of cerebral infarctions may be expected to
result in seizures. Other specific vascular disorders oc-
curring in pregnancy and complicated by seizures in-
clude cerebral venous thrombosis, subarachnoid haem-
orrhage and eclamptic hypertensive encephalopathy.
Investigation into causes of epilepsy in pregnant
women should follow the same principles as for a non-
gravid patient. MRI is favoured over X-ray CT scanning
due to its superior resolution and the lack of ionizing
radiation. However, the potential effects of a strong
magnetic field on a developing fetus are not entirely
clear but can be justified if there is a clear clinical in-
dication, whereas lead shielding can protect the uterus
during an X-ray CT scan.
The principles of initiating AED treatment in preg-
nancy are the same as those for the non-pregnant pa-
tient. Specific underlying causes for the epilepsy, suchas stroke and eclamptic hypertensive encephalopathy,
will require their own treatment. Status epilepticus aris-
ing as a consequence of eclampsia should be treated
initially with an intravenous benzodiazepine, prefer-
ably lorazepam, followed, if necessary, by intravenous
phenytoin or fosphenytoin. Magnesium sulphate has
been shown to prevent tonic–clonic seizures in eclamp-
sia112, 113, and does not impact on labour, other than to
increase the dose of oxytocin that is required114.
Breast-feeding and AEDs
All women with epilepsy should be strongly encour-
aged to breast feed their babies. However, drug elimi-
nation mechanisms are not fully developed in early in-
fancy, therefore repeated administration of a drug via
breast milk may lead to its accumulation in the infant
and pharmacological effects may occur115. Drug con-
centrations in milk can substantially differ between the
first and last portion of the feed, and between the left
and right breast, depending on the fat and protein con-
tent 116, 117, although the total amounts of drug trans-
ferred to the infant via breast milk are usually much
smaller than the amounts transferred via the placenta
during pregnancy.
Relatively small amounts of phenytoin are trans-
ferred via breast milk (18–20% of plasma concentra-
tion)115 and the serum levels of phenytoin in breast-
feeding infants are generally considerably below ther-
apeutic levels. Phenobarbitone, primidone and lamot-
rigine can accumulate in plasma in the breast-fed baby
due to slow elimination. Preliminary data in a small
number of cases indicate that lamotrigine passes into
breast milk at 40–45% of the level in the plasma; there
were no adverse effects in any of the infants118–120. It is
therefore recommended that the infant is closely mon-
itored and, if appropriate, serum drug levels measured.
If the mother is on barbiturates and if the baby is drowsy
or sedated, breast- and bottle-feeding can be alternated.
Carbamazepine concentrations in breast-fed babies are
usually low (breast milk level 39–40% of plasma con-
centration)121 and below the level where pharmaco-
logical effects might be anticipated. Ethosuximide can
be transferred via breast milk in relatively high daily
doses (79–100% of the plasma concentration)115, 122
and plasma concentrations in breast-fed babies can be
close to therapeutic levels. Sodium valproate levels in
breast-fed babies are low (1–10% of plasma concentra-
tion)115. Vigabatrin and gabapentin are excreted mainly
unchanged in the urine and therefore in infants with
fully developed renal function, accumulation of these
drugs is unlikely123. There are no data relating to top-
iramate or tiagabine.
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epilepsy—statements and recommendations
 Most women with epilepsy have normal vaginal
deliveries (II).
 Women should be referred by their obstet-
ric/gynaecological consultant to a specialist centre
for a high-quality ultrasound scan (C).
 The patient’s seizures should be monitored and ap-
propriate adjustments of AED dosage made (C).
 AED exposure (particularly enzyme-inducing
AEDs) leads to greater risk of haemorrhagic dis-
ease of the newborn, thus vitamin K1 should be
given to the mother in the last month of pregnancy
and to the neonate (B).
 Delivery should take place in an obstetric unit with
facilities for maternal and neonatal resuscitation
(C).
 The optimal maintenance dose of AEDs should be
reviewed after delivery (C).
 All AEDs currently available can be taken whilst
breast-feeding (C).
 All women with epilepsy should be encouraged to
breast-feed their babies (C).
 If drowsiness occurs in breast-fed babies whose
mothers are taking phenobarbitone, breast- and
bottle-feeding can be alternated (C).
The care of children of mothers with epilepsy
Although there is much anxiety about the possible risks
to a child from the mother’s epilepsy there is no pub-
lished evidence.
The risk of the child being harmed depends on the
type of seizure, its severity and frequency, and this risk
is probably small if time is taken to train mothers and
carers in safety precautions51. The women most at risk
of injuring young children are those with uncontrolled
juvenile myoclonic epilepsy, because children tend to
wake early and these mothers are most at risk of my-
oclonic jerks at that time51. Some clinicians recom-
mend that, during the puerperium, mothers whose ju-
venile myoclonic epilepsy is uncontrolled are advised
to have someone else look after the child in the early
morning.
Advice about safety precautions should be given to
mothers24, 51, even those who have not had a seizure
for some time, because it is possible that seizures may
return or their frequency increase due to stress and ex-
haustion in the puerperium. An experienced epilepsynurse, together with a health visitor or a midwife,
should make a home visit shortly before the birth to
advise on safety precautions in the home.
From an early stage, a routine of looking after the
baby should be established that maximizes opportuni-
ties for bonding but minimizes risk to the child. The
partner should be encouraged to assist with feeding the
child, especially at night, so that the mother can sleep,
e.g. breast milk can be expressed using a breast pump
so that it can be given at night by the partner.
There should also be an assessment of the character
of the woman’s seizures. Seizures in which the mother
loses awareness, wanders, has automatisms, convulses,
has no warning of the oncoming seizure or has post-
ictal confusion are particularly dangerous.
Table 3 lists practical suggestions for minimizing the
risk to the child, whilst providing maximum bonding
experience for the mother. The suggestions assume that
the mother is of normal intelligence and is not physi-
cally disabled.
Cognitive side effects of AEDs
Controversy exists over the differential cognitive side-
effects of AEDs because of inadequate study design124.
When the methodological flaws of studies are taken into
consideration, some AEDs (phenobarbitone and ben-
zodiazepines) may have cognitive side-effects125 and
affect the ability to care for children.
Educating the child and family
Children of women with epilepsy will rapidly realize
that their mother is special and it is important that they
are taught from an early age how to behave if their
mother has a seizure. From the age of two many chil-
dren will be capable of sitting quietly by the mother
until the seizure is over, and summoning help if ne-
cessary. By the age of five, a child should know what
to do if the mother has a seizure while they are out-
side the home. This approach will ensure that the child
will not be taken by surprise or be frightened by what
other people do. A child who grows up in a family that
copes with the mother’s seizures calmly, will also show
confidence in dealing with them. After the seizure has
ended, it is important that the mother cuddles and com-
forts the child so that he or she does not feel to blame
for the seizure.
Care of children of mothers with epilepsy—statements
and recommendations
 The risk of accidentally harming a child is low and
depends on the type of seizure, its severity and fre-
quency (III).
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Table 3: Practical suggestions for minimizing the risk to children of women with epilepsy.
Activity Safety precautions
Feeding  For babies, the mother should breast-, bottle- or spoon-feed the child whilst sitting on the floor or with her back
against a wall
 For older infants, use a low ‘highchair’ with the mother still sitting on the floor
 If the mother has automatisms or episodes of confusion, feeding should be supervised by another adult
Bathing  Care for the child on the floor as much as possible. Bathing should always be supervised by another adult, even
when a floor mat and bowl are used. A sponge down may be a suitable alternative to bathing
Travelling or  Another person should carry the child up or down stairs or the child should be carried securely strapped
carrying child in a padded carrycot
 For babies, use a pram with a dead man’s handle to prevent pram running away
 For toddlers, use reins to stop them wandering away
Around the  Place child in a playpen or use safety gates to section off high-risk
home areas of the home such as the kitchen, stairways, and lock doors leading outside or into the garden Stress and exhaustion in the puerperium may make
seizures reappear, even in women who have been
seizure-free for some time (III).
 Assistance for the mother is particularly important
when bathing, carrying or travelling with children.
Women with epilepsy who are intellectually and
physically challenged need a greater level of assis-
tance (C).
 The child and the child’s family need to be educated
about managing the mother’s seizures calmly and
effectively (C).
Epilepsy and the menopause
Female sex hormones alter the expression of epilepsy
and the efficacy of AEDs48. There is scant literature
about the effects of epilepsy on the menopause or
the effects of the hormonal changes of the menopause
on epilepsy10. The few studies that have been carried
out have had methodological problems including small
numbers and little recognition of the heterogenous na-
ture of epilepsy126.
The effects of the menopause on epilepsy
Opinion differs on the effect of the menopause on
seizure frequency due to the lack of research in the area.
Some women may find the menopause has no effect on
seizure frequency, others that there is an increase in
seizures, or a recurrence of seizures at the time of the
menopause, or even a remission of seizures.
Epilepsy and osteoporosis
Women with epilepsy are at increased risk of bone
demineralization, since seizures and AEDs affect the
hypothalamic-pituitary-adrenal axis and this can have
an adverse impact on bone metabolism48. The mech-
anisms of osteoporosis are multiple and incompletelyunderstood. Microsomal enzyme induction by pheno-
barbitone, phenytoin and carbamazepine accelerates
the metabolism of vitamin D and can have profound
effects on calcium metabolism, pre-disposing towards
osteomalacia.
The reduction in oestrogen levels in the early post-
menopausal period may explain the increased fre-
quency of bone fractures at this time31. It has been
suggested that women on long-term AEDs should have
bone density monitored on a regular basis although the
optimal frequency has not been assessed.
Hormone replacement therapy (HRT) and epilepsy
The reduction in circulating oestrogen at the time
of the menopause results in menopausal symptoms
and an increased risk of developing heart disease and
bone demineralization. Provided it is clinically indi-
cated, menopausal and post-menopausal women with
epilepsy should receive hormone replacements as this
therapy appears to have beneficial effects127. The HRT
regimen should be given in standard doses. Adminis-
tration of calcium and vitamin D supplements should
also be considered for women with epilepsy.
The possibility that treatment with oestrogen in-
creases seizure frequency is supported by the find-
ings of a recent questionnaire survey of members of
an epilepsy organization; 620 women who responded
to a postal survey were menopausal or post-menopausal
and double the number of past HRT users had an in-
crease in seizure frequency compared with those who
had not received HRT128. It is advisable to add a pro-
gestogen to the HRT regimen to counteract the potential
proconvulsant effects of oestrogen, even if the woman
has no uterus24. Addition of progestogen to the HRT
regimen does not appear to attenuate the cardioprotec-
tive effects of oestrogen129. There is no evidence that
the route of administration of HRT is important.
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recommendations
 The effects of epilepsy on the menopause and the
effects of the hormonal changes of the menopause
on epilepsy cannot be reliably predicted (III).
 Women with epilepsy are recognized to be at risk of
bone demineralization, especially if they are receiv-
ing the hepatic enzyme-inducing AEDs, phenobar-
bitone, primidone, phenytoin and carbamazepine,
which can accelerate vitamin D metabolism (III).
 All post-menopausal women with epilepsy should
receive HRT (combined oestrogen and progesto-
gen), if it is clinically indicated, even if the woman
has no uterus (C).
Multidisciplinary partnership in the general
management of epilepsy
The optimal care of women with epilepsy, particularly
when pregnant, requires collaboration between a range
of professionals from a wide range of backgrounds2,
and will be determined by the needs of the patient and
the resources available locally. The voluntary sector
also plays an important role. Recognition of the ben-
efits of involving a range of professionals in meeting
the needs of any individual person with epilepsy is not
new1, 130, 131. However, this strategy tends not to take
place in practice and is a cause for concern132.
Good communication is the key to effective multi-
disciplinary care with good information exchange be-
tween primary health care teams and specialists133. The
clinical nurse specialist in epilepsy has a central role in
developing effective partnerships2, 134, 135.
The integrated care scheme approach has previ-
ously been discussed from a national132 and dis-
trict134, 136, 137 perspective.
Key players of the care-giving partnership are the
general practitioner and his team, the epilepsy consul-
tant, the epilepsy nurse, the obstetric/gynaecological
consultant and the midwife, although they may not see
themselves in the team role. The general practice team
and the midwives may need specialized education and
training. The epilepsy nurse’s role should include en-
suring that epilepsy care is not compromized and pro-
viding information and advice such as pre-conception
counselling. By discussing issues relating to their con-
dition with the epilepsy nurse or other health care pro-
fessional, women with epilepsy will be sufficiently em-
powered to make decisions about their own treatment.
There should be active liaison between the epilepsy
nurse and the hospital/community midwives, and at a
later stage of pregnancy, with the health visitor and
general practice team. Arguably, the general practi-tioner should be the team leader51, but usually the
epilepsy consultant and epilepsy liaison nurse lead and
liaise. In this scenario, the general practitioner, obstet-
ric/gynaecological consultant and midwife would con-
tinue with their traditional roles, with all team members
taking into account the specific needs of the woman
with epilepsy. For practical purposes, the most appro-
priate team leader may be the epilepsy liaison nurse,
since it is he or she who will keep the lines of commu-
nication open between the other members of the team.
Multidisciplinary partnership—statements
 Optimal care for women with epilepsy requires col-
laboration between a range of professionals from a
wide range of backgrounds (III).
 Jointly planned shared care is the preferred model
of care for people with epilepsy (III).
 The clinical nurse specialist in epilepsy has a cen-
tral role in developing effective partnerships (III).
SUMMARY POINTS
 Management of women with epilepsy is multifac-
torial
 Epilepsy should be rigorously reviewed and women
provided with adequate information for them to
form their own views on the issues and the man-
agement regimen they wish to pursue
 Women with epilepsy should be counselled on
reproductive issues, contraception, teratogenicity,
pregnancy, labour and child-rearing, and bone
health
 If women are receiving AED medication,
monotherapy is preferred
 Changes to AED therapy should be made before
contraception is stopped
 Women with epilepsy, who decide to embark upon
pregnancy, should be seizure-free if possible
 Women with complex needs should be referred to
specialist centres for detailed review and assess-
ment
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APPENDIX
Organizations
Joint Epilepsy Council,
P.O. Box 27027,
Edinburgh EH10 5YN
Tel: (0131) 466 7155
Fax: (0131) 466 7156
National Society for Epilepsy, Chalfont St
Peter, Gerrards Cross, Bucks SL9 0RJ
Tel: (01494) 601 300
Fax: (01494) 871 927
British Epilepsy Association, Anstey
House, 40 Hanover Square, Leeds,
West Yorkshire LS3 1BE
Tel: (0113) 243 9393
Fax: (0113) 242 8804
International League Against Epilepsy
(British Branch), Professor S Shorvon
(Secretary), c/o National Hospital for
Neurology and Neurosurgery, Queen Square,
London
Tel: (0171) 837 3611
Fax: (0171) 829 8720
The Epilepsy Association of Scotland,
48 Govan Road, Glasgow G51 1JL
Tel: (0141) 427 4911
Fax: (0141) 427 7414
UK Epilepsy and Pregnancy Register, c/o Dr
JI Morrow, Department of Neurology, Royal
Victoria Hospital, Grosvenor Road, Belfast
BT12 6BA
